thalidomide has been researched along with Adrenocortical Carcinoma in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was administered as tolerated with a starting dose of 50 mg and target dose of 200 mg /d." | 6.90 | Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. ( Baudin, E; Beuschlein, F; Deutschbein, T; Fassnacht, M; Hahner, S; Heidemeier, A; Hescot, S; Körbl, D; Kroiss, M; Megerle, F; Neu, B; Quinkler, M; Ronchi, CL; Schlötelburg, W, 2019) |
| "Thalidomide was administered as tolerated with a starting dose of 50 mg and target dose of 200 mg /d." | 2.90 | Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. ( Baudin, E; Beuschlein, F; Deutschbein, T; Fassnacht, M; Hahner, S; Heidemeier, A; Hescot, S; Körbl, D; Kroiss, M; Megerle, F; Neu, B; Quinkler, M; Ronchi, CL; Schlötelburg, W, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kroiss, M | 1 |
| Deutschbein, T | 1 |
| Schlötelburg, W | 1 |
| Ronchi, CL | 1 |
| Hescot, S | 1 |
| Körbl, D | 1 |
| Megerle, F | 1 |
| Beuschlein, F | 1 |
| Neu, B | 1 |
| Quinkler, M | 1 |
| Baudin, E | 1 |
| Hahner, S | 1 |
| Heidemeier, A | 1 |
| Fassnacht, M | 1 |
1 trial available for thalidomide and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Disease-Free Survival; Europe; Fema | 2019 |